TrianglePTX-100 trial for CTCL (NCT06854653): short film
PTX-100 trial for CTCL (NCT06854653). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with stage IB or higher cutaneous T-cell lymphoma after at least two systemic treatments failed or were intolerable. Prior stem-cell transplantation and central nervous system involvement are excluded.
The idea: PTX-100 blocks GGTase-I, an enzyme modifying cancer growth proteins. Randomization compares 500 and 1,000 milligrams per square meter. Later patients receive the selected dose. Infusions run on days 1–5, every two weeks for four cycles, then every three weeks. Responses are assessed.
This phase 2 study plans 115 patients. Prescient Therapeutics sponsors it; five US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.